Tanvex BioPharma, Inc. (TPE:6541)

Taiwan · Delayed Price · Currency is TWD

35.95

+0.45 (1.27%)

Aug 19, 2026, 1:30 PM CST

-34.64% (1Y)

Market Cap	9.41B -28.3%
Revenue (ttm)	483.94M +496.1%
Net Income	-1.42B
EPS	-5.58
Shares Out	264.99M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	324,534
Open	35.20
Previous Close	35.50
Day's Range	34.85 - 36.25
52-Week Range	35.10 - 68.00
Beta	0.22
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About Tanvex BioPharma

Tanvex BioPharma, Inc., a pharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar products in Taiwan and the United States. The company focuses on delivering biopharmaceuticals with biosimilars targeting neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. It also engages in contract development and manufacturing of biological medicines. The company was founded in 2011 and is headquartered in George Town, the Cayman Islands. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2011

Country Cayman Islands

Stock Exchange Taiwan Stock Exchange

Ticker Symbol 6541

Full Company Profile

Financial Performance

In 2025, Tanvex BioPharma's revenue was 400.97 million, an increase of 1056.27% compared to the previous year's 34.68 million. Losses were -1.50 billion, 8.59% more than in 2024.

Financial Statements